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Background: Previous studies have shown that lactate dehydrogenase-A (LDH-A) is strongly expressed in several
malignancies, that LDH-A expression is associated with poor prognosis, and that LDH-A inhibition severely
diminishes tumorigenicity. However, little is known about the implications of LDH-A expression in intrahepatic
cholangiocarcinoma. The purpose of this study was to investigate the expression of LDH-A and to clarify its effect
on intrahepatic cholangiocarcinoma.
Methods: We studied the expression of LDH-A in tissue samples from patients with intrahepatic cholangiocarcinoma
(n = 54) using the ultrasensitive surfactant protein (S-P) immunohistochemical method. We then inhibited LDH-A using
small hairpin RNA (shRNA) in the cholangiocarcinoma cell line HuCCT-1 in vitro to study the role it plays in promoting
growth and escaping apoptosis.
Results: We report that LDH-A was overexpressed in 52 of 54 (96%) paraffin-embedded cancer tissue samples and 0 of
54 para-carcinoma tissue samples. Reduction of LDH-A by RNA interference (RNAi) inhibited cell growth and induced
apoptosis in HuCCT-1 cells. This result correlated with the elevation of cytoplasmic reactive oxygen species (ROS) levels.
Conclusions: LDH-A expression is closely correlated with histopathological variables of intrahepatic cholangiocarcinoma,
indicating that LDH-A may serve as a new treatment target.
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Intrahepatic cholangiocarcinoma (ICC) is a devastating ma-
lignancy that arises from the epithelial lining of the intrahe-
patic bile ducts; recent data have demonstrated an increase
in the incidence and mortality of ICC worldwide [1]. Due
to the difficulty in detecting ICC at the early stage and the
disappointing chemotherapy strategies offered currently,
the prognoses of patients with advanced cholangiocarci-
noma are very poor [2,3]. Therefore, new insights into can-
cer cell-specific biological pathways are urgently needed to
promote development of rationally targeted and more ef-
fective therapeutics.* Correspondence: fuzan2011@163.com
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unless otherwise stated.Even under aerobic conditions, cancer cells preferen-
tially undergo glycolysis followed by fermentation; this
phenomenon is known as aerobic glycolysis (or the
Warburg effect) [4]. Lactic dehydrogenase A, LDH-5
(LDH-A), the NADH-dependent enzyme that catalyzes
the conversion of pyruvate to lactate, is a key glycolytic
enzyme for aerobic glycolysis. Inhibition of LDH-A has
been shown to cause a blockade of aerobic glycolysis of
tumor cells [5] and to severely diminish the tumorigen-
icity of neu-initiated mammary tumor cells [6,7]. Previ-
ous studies have shown that LDH-A is strongly
expressed in gastric, pulmonary, gynecologic, and breast
malignancies associated with poor prognoses [8-10].
However, the expression of LDH-A in clinical tissue
samples of ICC has not been previously described, and
the effects of LDH-A in ICC have been unclear.
In metazoan cells, reactive oxygen species (ROS) are gen-
erated by mitochondria during oxidative phosphorylationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Correlation between LDH-A expression level and
clinicopathologic characteristics in ICC patients
Variables LDH-A
High Low P value
Sex Male 10 10 0.554
Female 13 9
Age, years >55 9 13 0.058
≤55 14 6
Tumor size, cm >6 9 9 0.591
≤6 14 10
Grade 1 6 11 0.037
2/3 17 8
Lymph node Yes 9 4 0.207
metastasis No 14 15
ICC, intrahepatic cholangiocarcinoma; LDH-A, lactate dehydrogenase-A.
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promote cell growth. In contrast, they activate and modu-
late apoptosis when cells are under stress [12]. As a key ef-
fector of cell death, ROS inflict oxidative damage on
cellular proteins, lipids, and nucleic acids. In advanced tu-
mors, however, these agents are downregulated, and conse-
quent cell-death signaling is suppressed [13]. Considering
that aerobic glycolysis diminishes cellular ROS in yeast
[14], we hypothesized that silencing LDH-A by blocking
aerobic glycolysis might upregulate ROS levels and induce
apoptosis of ICC.
In the ICC tissues examined in the present study, LDH-A
was overexpressed and the expression of LDH-A was asso-
ciated with tumor differentiation. Reduction of LDH-A by
RNA interference (RNAi) inhibited cell growth in liquid
culture and induced cell apoptosis. Furthermore, the inhib-
ition of LDH-A elevated cytoplasmic ROS levels. In other
words, overexpression of LDH-A in cholangiocarcinoma
might be associated with ROS downregulation. Taken to-
gether, these results suggest that LDH-A is a potential
therapeutic target for ICC treatments.
Methods
Reagents and cell lines
Cholangiocarcinoma cell lines (HuCCT-1 cells) were
purchased from the Chinese Academy of Sciences.
Dulbecco’s modified Eagle’s medium (DMEM), phos-
phate-buffered saline (PBS), fetal bovine serum (FBS),
non-essential amino acid solution (NEAA 10 mM,
100×), penicillin-streptomycin solution (10,000 units/ml
penicillin and 10,000 μg/ml of streptomycin) and
trypsin-ethylenediaminetetraacetic acid (EDTA) solution
(0.05% trypsin, 0.53 mM EDTA) were obtained from
Invitrogen-Life Technologies (Carlsbad, CA, USA).
ICC tissue samples
Paraffin-embedded samples of ICC were obtained from 42
patients who underwent surgical excision without any prior
therapy between 2010 and 2011 at The First Affiliated Hos-
pital of Nanjing Medical University. The para-carcinoma
tissue we choose were 1 cm or more away from the cancer-
ous tissue. Histological diagnoses and grading were per-
formed on hematoxylin-eosin-stained tissue sections. All
patients had given informed consent. The study was ap-
proved by the Institutional Review Board of The First Affili-
ated Hospital of Nanjing Medical University. The patients’
clinical data are listed in Table 1. A total of 32/42 patients
were mass-forming, 8/42 were periductal-infiltrating, and
2/42 were intraductal-growing cholangiocarcinomas. Histo-
logically, all patients enrolled had tubular adenocarcinomas.
Immunohistochemistry
First, the 4-μm tissue sections were deparaffinized with
xylene and rehydrated. Antigen retrieval was performedby autoclaving for 10 minutes. Endogenous peroxidase
activity was quenched with methanol and hydrogen per-
oxide (2.5% to 3.5%) for five to eight minutes, then the
sections were washed for three minutes in PBS three
times. The primary antibody against LDH-A (dilution
1:100; ab9002, Abcam, Cambridge, UK) was applied at
room temperature and the sections placed in the re-
frigerator at 4°C overnight.
Following washing with PBS (three times for three mi-
nutes), tissue sections were incubated with a rabbit anti-
sheep IgG (Bioworld Products, Visalia, CA, USA) at 37°C
for 30 minutes. Then the sections were washed in PBS.
Streptavidin peroxidase reagent was applied for 10 minutes.
The color was developed via a three- to five-minute incuba-
tion with 3,3′-diaminobenzidine (DAB) solution. Finally,
the sections were counterstained with hematoxylin for five
to eight minutes and mounted on glass specimen plates.
Treated tissue sections were observed under an optical
field with 200× magnification. According to the percent-
age of positive cells in the cytoplasm and the nuclear ex-
pression, which was assessed in a grading system [15],
two LDH-A expression levels were established: strong
cytoplasmic expression in >50% of cancer cells or nu-
clear expression in >10% of cancer cells was defined as
high expression; otherwise, nuclear expression was con-
sidered low.
Silencing LDH-A with RNA interference
The target sequence for LDH-A small interfering RNA
was 5′-GGAGAAAGCCGUCUUAAUU-3′. The control
nucleotide sequence of small interfering RNA was 5′-
GTTCTCCGAACGTGTCACGT-3′. This random se-
quence is not related to LDH-A mRNA. The pGPU6/
Neo eukaryotic expression vector with LDH-A siRNA
(shRNA) or LDH-A siRNA con (NC) was tran-
siently transfected into the HuCCT-1 cell line using
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turer’s protocol (Invitrogen). The interference effect was
verified by RT-PCR and western blot assay at 48 and
72 hours post-transfection.
Real-time PCR
The mRNA levels of LDH-A and β-actin were analyzed
using real-time PCR. Briefly, 2 μg of high-quality RNA
was processed directly to cDNA in a total volume of
25 μl using a reverse transcription kit (Takara, Dalian,
China) according to the manufacturer’s instructions.
Amplification reactions were performed in a 50-μl vol-
ume of SYBR Premix Ex Taq (Takara, DRR041A). The
PCR reaction included the following components: 10
pmol of primer, 2 mM MgCl2, 200 μM dNTP mixture,
0.5 U of Taq DNA polymerase and universal buffer. The
thermal cycling conditions were as follows: 95°C for
30 seconds; 40 cycles at 95°C for 5 seconds, 60°C for
31 seconds; and a final dissociation stage. The specificity
of amplification was examined by melting curve analysis
and by electrophoresis in 2% agarose gel. All of the reac-
tions were performed in triplicate in an ABI PRISM
7300 real-time PCR system. The primer sequences for
the human LDH-A gene were as follows: forward primer,
5′-AGCCCGATTCCGTTACCT-3′ and reverse primer:
5′-CACCAGCAACATTCATTCCA-3′. As an internal
standard, a fragment of human β-actin was amplified by
PCR using the following primers: forward primer, 5′-
CCAAAGCAACCGTGAGGA-3′ and reverse primer,
5′-CCAGAGGCGTACAGGACA-3′. Data are presented
as the fold change of LDH-A expression in each tumor
tissue relative to its paired control group tissue after
normalization with β-actin.
Western blot analysis
Cells were harvested and lysed in a buffer containing
50 mM Tris–HCl pH 7.5, 150 mM NaCl, 2 mM EDTA,Figure 1 Immunohistochemical staining of lactate dehydrogenase-5 (
human ICC. (B) Corresponding (original magnification, 200×). (A) Weak cyt
expression. ICC, intrahepatic cholangiocarcinoma.1% Triton and 1 mM PMSF for 20 minutes on ice. Ly-
sates were cleared by centrifugation at 17,970 × g, 4°C
for 10 minutes. Supernatants were collected, and protein
concentrations were determined using a Bradford assay
(Beyotime, Wuhan, China). The proteins were then sep-
arated with an SDS/polyacrylamide gel and transferred
to a polyvinylidene fluoride (PVDF) membrane (Bio-Rad,
Berkeley, CA, USA). After blocking in PBS with 5% non-
fat dry milk for 1 hour, the membranes were incubated
overnight at 4°C with the primary antibodies in PBS with
5% non-fat dry milk. Anti-LDH-A rabbit antibody
(1:1000, Cell Signaling Technology, Danvers, MA, USA)
and anti-β-actin polyclonal antibody (1:2000, Bioss Inter-
national, Shanghai, China) were used. Membranes were
extensively washed with PBST and incubated with horse-
radish peroxidase-conjugated secondary anti-mouse
antibody or anti-rabbit antibody (1:2,000, Bio-Rad). After
additional washes with PBST, antigen-antibody com-
plexes were visualized with a chemiluminescence kit
(Pierce, Thermo-Fisher Scientific, Waltham, MA, USA).
Cell viability assay
To analyze the effect of LDH-A on the viability of
HuCCT-1, a total of 3 to 5 × 103 cells per well were
seeded in 96-well plates. After 12 hours, the cells were
transfected with shRNA or NC plasmids and incubated
for 96 hours. Cell viability was determined using a Cell
Counting Kit-8 assay according to the manufacturer’s
protocol (Dojindo Laboratories, Kumamoto, Japan) at
24, 48, 72, and 96 hours after transfection.
Cell apoptosis assay
To analyze apoptosis, cells with or without treatment
were stained with annexin-V–fluorescein isothiocyanate
(FITC) and 7-aminoactinomycin D (7-AAD), according
to the manufacturer’s instructions (Becton Dickinson
Biosciences, San Jose, CA, USA). Data acquisition andLDH-A) in (A) para-carcinoma tissue and (B) tissue sections from
oplasmic and nuclear expression. (B) Strong cytoplasmic and nuclear
Figure 2 Knock-down of LDH-A inhibits growth and induces apoptosis in the HuCCT-1 cell line. (A) LDH-A expression was analyzed after
transfection by RT-PCR, with actin as loading control. The figure shows that RNAi induced a specific decrease in LDH-A expression after
transfection. (B) Western blot assay also shows a specific decrease in LDH-A expression after transfection, with actin as loading control. LDH-A,
lactate dehydrogenase A; RNAi, RNA interference.
Figure 3 LDH-A knockdown inhibits HuCCT-1 cell growth. Relative
cell numbers at 72 and 96 hours post-transfection for RNAi versus NC
have a P value of 0.008 and 0.004, respectively. LDH-A, lactate
dehydrogenase A; NC, negative control; RNAi, RNA interference.
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ometer with Cell-Quest software (BD Biosciences). Cells
that were positively stained by annexin-V-FITC only
(early apoptosis) and were positive for both annexin-V–
FITC and 7-AAD (late apoptosis) were quantitated, and
both subpopulations were considered as dead cells.
Measurement of levels of intracellular ROS
Intracellular ROS production was measured by staining
cells with carboxy-H2 dichlorofluorescin diacetate
(DCFDA; molecular probes) according to the manufac-
turer’s instructions (Beyotime, Wuhan. China). Briefly,
treated HuCCT-1 cells were cultured in the presence of
20 μM carboxy-H2DCFDA for 30 minutes. After remov-
ing the culture medium, cells were washed twice with
PBS, resuspended in growth medium and measured by
flow cytometry.
Statistics
Results are expressed as mean ± standard deviation (SD).
The χ2 test was used to test relationships between cat-
egorical variables including age, gender, tumor size,
grade, lymph node metastasis and the expression of
LDH-A. Independent-sample t-tests were used to com-
pare LDH-A mRNA, the proliferation, apoptosis, and
ROS levels between the RNAi and the negative control
(NC) groups. Statistical significance was considered
P <0.05.
Results
Immunohistochemical expression of LDH-A and its associ-
ation with histopathological variables
First, we studied the expression of LDH-A in ICC tissue
samples using the S-P immunohistochemical method.
Immunohistochemical expression was observed to be
nuclear and/or cytoplasmic (Figure 1). Of 42 ICC tissue
samples, 23 (54.8%) demonstrated high LDH-A reactivityas categorized using the grading system previously
mentioned [15]. In 16 ICC tissue samples, adjacent non-
cancerous tissues were consistently unreactive to LDH-
A. The association of LDH-A with histopathological
variables is shown in Table 1. LDH-A expression was
positively correlated with histopathological variables
(P <0.05). That is, the overexpression of LDH-A was
more prevalent in poorly differentiated ICC cells. How-
ever, no significant association was noted between LDH-
A expression and lymph-node metastasis.
Reduction of LDH-A inhibited growth and induced apop-
tosis of HuCCT-1
To investigate the effect of aberrant LDH-A expression in
cholangiocarcinoma, RNAi experiments were performed
using the HuCCT-1 cell line. We examined the expression
of LDH-A at its mRNA and protein levels by performing
RT-PCR and western blotting analyses in the HuCCT-1 cell
Figure 4 Cell death was determined by flow cytometry of annexin V- and 7-AAD-stained cells at 72 hours post-transfection with
shLDH-A (RNAi) or siControl (NC). The histogram (right) represents the average percentage (±SD) of dead cells. The number of dead cells
treated with shLDH-A (RNAi) compared with the control group (NC) has a P value of <0.05 using Student’s t test. 7-ADD, 7-aminoactinomycin D;
RNAi, RNA interference; SD, standard deviation; sh, small hairpin.
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liferation rates of the HuCCT-1 LDH-A knocked-down cell
line (RNAi group) were slower than those of the negative
control HuCCT-1 cell lines (NC group) (Figure 3). The ab-
sorbance value of transfected cells at 72 and 96 hours
decreased markedly compared to the negative control
cells (P <0.01). The apoptosis rates of the RNAi group
(25.89% ± 1.86%) obviously increased compared to those of
the NC group (7.47% ± 2.02%) (Figure 4). Collectively, in-
hibition of LDH-A resulted in a decrease in the rate ofFigure 5 Intracellular ROS production was detected with DCFDA fluor
transfection with shLDH-A (RNAi) or siControl (NC). DCFDA, dichloroflu
sh, short hairpin.proliferation of HuCCT-1 cells, while apoptosis rates in-
creased. These results implicate the role of LDH-A in
tumorigenesis.
ROS levels associated with the LDH-A expression
Silencing LDH-A has been reported to increase the
OXPHOS capacity and to induce oxidative stress [6,14].
Therefore, we hypothesized that ROS, generated during
respiration [16], might increase following a reduction in
the expression of LDH-A in cholangiocarcinoma. ROSescence and monitored by flow cytometry at 72 hours post-
orescin diacetate; RNAi, RNA interference; ROS, reactive oxygen species;
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those in the NC group (Figure 5). These data suggest
that LDH-A expression is linked to the ROS level of ICC
and that inhibition of LDH-A increases ROS levels.
Discussion and conclusions
The principal result of our experiments was the finding
that the expression of LDH-A was higher in ICC. This
result agrees with the observation of Wang et al. that
the LDH-A gene is up-regulated in ICC cells compared
to normal liver tissues [17]. An increase of LDH-A in
tumor cells is linked with an aggressive phenotype in
colorectal adenocarcinomas. In other studies of gastric
carcinoma, the overexpression of LDH-5 was more
prevalent in advanced tumors having positive vessel in-
vasion, and patients with overexpression of LDH-5
showed far lower disease-free and overall survival rates
compared with patients with low LDH-5 expression;
therefore, LDH-A expression may be a useful prognostic
factor for patients with gastric carcinoma [10,15]. Our
study revealed a significant correlation between LDH-A
and clinicopathologic characteristics (Table 1); poorly
differentiated ICC cells tended to have higher expression
of LDH-A. In conclusion, LDH-A is overexpressed in
ICC and could, therefore, serve as an additional marker
for malignancy.
Earlier studies have shown that attenuation of LDH-A
expression causes impairment of tumor maintenance
and leads to a reduction in tumor growth in xenograft
models of renal cancer [6,18]. Here, we observed that
knockdown of LDH-A in the ICC cell line HuCCT-1 is
associated with the reduction of the proliferation rate
and an increase in the apoptosis rate. Our research sup-
ports the hypothesis that the upregulation of LDH-A
creates an adaptive advantage by which cancer cells
evade apoptosis. The high expression of LDH-A in can-
cer cells causes cancer cells to use aerobic glycolysis ra-
ther than OXPHOS as their main means of glucose
metabolism. This allows these cells to sustain higher
proliferative rates and to resist some cell death signals,
particularly those mediated by increased oxidative dam-
age [14,19]. Therefore, cancer-specific isoforms of en-
zymes involved in the Warburg effect (such as LDH-A)
may represent new drug targets for ICC treatment
[20,21]. Individuals with a hereditary LDH-A deficiency
show myoglobinuria only after intense anaerobic exer-
cise (exertional myoglobinuria), and they do not show
any symptoms under ordinary circumstances. So LDH-A
may be, in principle, a specific, tolerated, and effective
antitumor target for ICC.
These pro-apoptosis effects of the down-regulation of
LDH-A in ICC could be attributed to a decrease in ROS.
Reduction of LDH-A has been reported to promote oxi-
dative phosphorylation [6], with the result of inducingapoptosis through the mitochondrial pathway [22]. Our
finding that ROS levels increased remarkably in the
RNAi group agreed with these reports. We infer that an
increased sensitivity to oxidative stress may be a major
mechanism for the pro-apoptotic effect of reduced
LDH-A expression.
In general, the results of our experiments indicate that
LDH-A is highly expressed in ICC and that inhibition of
LDH-A causes remarkable apoptosis of the HuCCT-1
cell line. Therefore, LDH-A might be a specific thera-
peutic target for ICC. Furthermore, our results indicate
that ROS levels are linked with the expression of LDH-A
and may be the cause of the pro-apoptotic effect in-
duced by the reduction of LDH-A expression in ICC.
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